Revenue: As of FY2025 Q3, the actual value is USD 1.103 B, beating the estimate of USD 2.844 M.EPS: As of FY2025 Q3, the actual value is USD -0.02.EBIT: As of FY2025 Q3, the actual value is USD -7.116 B.<h3>ONM Environmental</h3><ul><li>Revenue: Decreased by 80% and 55% to $776,000 and $5,583,000 for the three and nine months ended September 30, 2025, respectively, compared to the same periods in 2024, primarily due to decreased sales volume of the Pooph branded pet odor product.</li><li>Cost of Goods Sold: As a percentage of revenue, costs were 54% and 51% for the three and nine months ended September 30, 2025, respectively, showing a decrease compared to the same periods in 2024.</li><li>Operating Income: Reported an operating loss of $3,807,000 and $2,026,000 for the three and nine months ended September 30, 2025, respectively, compared to operating income in the same periods in 2024, due to decreased sales and credit loss expenses.</li></ul><h3>BLEST (Engineering)</h3><ul><li>Revenue: Decreased by 34% to $327,000 for the three months ended September 30, 2025, and decreased by 7% to $1,565,000 for the nine months ended September 30, 2025, compared to the same periods in 2024.</li><li>Cost of Revenues: Costs were 95% and 66% of revenues for the three and nine months ended September 30, 2025, respectively, compared to 100% and 74% in the same periods in 2024.</li><li>Operating Loss: Reported an operating loss of $403,000 and $763,000 for the three and nine months ended September 30, 2025, respectively.</li></ul><h3>Clyra Medical</h3><ul><li>Revenue: No commercial sales reported for the three and nine months ended September 30, 2025.</li><li>Expenses: Incurred total costs and expenses of $1,483,000 and $4,063,000 for the three and nine months ended September 30, 2025, respectively, including research and development expenses.</li></ul><h3>BETI</h3><ul><li>Revenue: No revenue generated as of the three and nine months ended September 30, 2025.</li><li>Expenses: Incurred total costs and expenses of $128,000 and $346,000 for the three and nine months ended September 30, 2025, respectively.</li></ul><h3>BEST</h3><ul><li>Revenue: No revenue generated as of the three and nine months ended September 30, 2025.</li><li>Expenses: Incurred $83,000 and $208,000 of total expenses for the three and nine months ended September 30, 2025, respectively.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: BioLargo aims to increase revenues, generate cash from operations, and/or generate cash from financing activities to continue operations. The company is focused on redeploying its technology with new partners and expanding the reach of its odor-control technology into new markets.</li><li>Non-Core Business: BETI is exploring joint ventures for its Cellinity battery technology, and Clyra Medical is working to generate revenue through product sales to multiple distributors.</li></ul>

BioLargo, Inc. | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 1.103 B